Criteria for the duration of anti-inflammatory therapy in children with bronchopulmonary dysplasia
DOI:
https://doi.org/10.14739/2310-1210.2019.2.161494Keywords:
bronchopulmonary dysplasia, premature infants, therapy, inhalation, corticosteroidsAbstract
Objective. To develop criteria for determining the duration of anti-inflammatory therapy and indications for withdrawal of inhaled corticosteroids (ICS) in children with bronchopulmonary dysplasia (BPD).
Materials and methods. A total of 56 premature infants with moderate to severe (group 1) and severe (group 2) “classical” bronchopulmonary dysplasia (BPD) who received inhaled budesonide were examined. The groups of children were comparable for gestational age, birth weight and matched for gender. The effectiveness of therapy was evaluated according to the dynamics of clinical manifestations, monitoring of blood oxygen saturation (SаO2) at rest and during exercise, capnographic monitoring and chest radiography changes.
Results. Monthly observation of children with BPD during the year showed symptoms resolution in all children in the course of anti-inflammatory ICS therapy (on average within 2.5 months in the children of group 1 and within 4.5 months in the children of group 2), and then the parameters of SаO2 were normalized (on average within 3 and 5.5 months, respectively). Capnographic changes remained longer (from 3 to 12 months). Chest radiographs showed changes within a period from 9 to 12 months and these changes did not always correspond to the symptoms resolution. The conducted factor analysis allowed to identify the criteria for withdrawal of anti-inflammatory therapy. The most significant criteria were the normalization of respiratory rate and reduction in dyspnea, a decrease in SaO2 less than 10 % during exercise, a decrease in unevenness of ventilation-perfusion relations and expiratory time according to Tin/Tex ratio. Changes in the chest radiographs did not have a significant effect on the duration of anti-inflammatory therapy in children with BPD.
Conclusions. Thus, the duration of ICS therapy should be individualized taking into account the severity of BPD, the dynamics of clinical manifestations, and the indicators of pulse oximetry at rest and during exercise. Capnography monitoring in children with BPD provides an opportunity to assess objectively the dynamics of bronchial obstruction resolution and to determine the individual terms for withdrawal of ICS. Constant X-ray control is not necessary at the outpatient stage of treatment for children with BPD, as the signs of radiographic recovery are slow and do not influence the choice and duration of anti-inflammatory therapy.
References
Bykovskaya, O. A. (2014). Bronholeheneva dysplaziia: patomorfolohichni osoblyvosti rozvytku u hlyboko nedonoshenykh ditei [Bronchopulmonary dysplasia: pathomorphological peculiarities of development in very preterm infants]. Neonatolohiia, khirurhiia ta perynatalna medytsyna, 4(1), 44–48. [in Ukrainian].
Senatorova, H. S., Lohvіnova, O. L., Lapshyn, V. F., Muratov, G. R., & Bashkіrova, N. V. (2015). Bronkholeheneva dysplaziia: neonatalnyi ta postneonatalnyi monitorynh [Bronchopulmonary dysplasia: neonatal and post-neonatal monitoring]. Kyiv. [in Ukrainian].
Panchenko, A. S., Gajmolenko, I. N., Tikhonenko, O. A., & Ignat'eva, A. V. (2013). Bronholegochnaya displaziya u detej: klinika, diagnostika, iskhody [Bronchopulmonary dysplasia in children: clinic, diagnosis, outcomes]. Zabajkal'skij medicinskij vestnik, 1, 175–183. [in Russian].
Ovsyannikov, D. Yu. (2017). Pulmonologicheskaya reabilitaciya detej s bronkholegochnoj displaziej: problemy i resheniya [Pulmonologic rehabilitation of children with bronchopulmonary dysplasia: problems and solutions]. Detskaya i podrostkovaya reacilitatsiya, 1(29), 10–18 [in Russian].
Senatorova, G. S., Chernenko, L. M., Muratov, G. R., & Bashkirova, N. V. (2015). Analiz e'ffektivnosti protivovospalitel'noj terapii u detej s bronkholegochnoj displaziej [Analyses of efficacy of anti-inflammatory therapy at children with bronchopulmonary dysplasia]. Medytsyna sogodnі і zavtra, 1(66), 52–55. [in Russian].
Zhang, Z. Q., Zhong, Y., Huang, X. M., & Du, L. Z. (2017) Airway administration of corticosteroids for prevention of bronchopulmonary dysplasia in premature infants: a meta-analysis with trial sequential analysis. BMC Pulm. Med., 17(1), 207. doi: 10.1186/s12890-017-0550-z
Bowen, Р., & Maxwell, N. (2014). Management of bronchopulmonary dysplasia. Ped. and Child Health, 24(1), 27–31. doi: https://doi.org/10.1016/j.paed.2013.06.007
Bassler, D., Plavka, R., Shinwell, E. S., Hallman, M., Jarreau, P. H., Carnielli, V., et al. (2015). Early inhaled budesonide for the prevention of bronchopulmonary dysplasia. N Engl J Med., 373(16), 1497–1506. doi: 10.1056/NEJMoa1501917
Jobe, A. H., & Bancalari, E. (2001). Bronchopulmonary dysplasia. Am J Respir Crit Care Med., 163(7), 1723–9.
Doyle, L. W., Cheong, J. L., Ehrenkranz, R. A., & Halliday, H. L. (2017) Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev., 10.
Check, J., Gotteiner, N., Liu, X., Su, E., Porta, N., Steinhorn, R., & Mestan, K. K. (2013). Fetal growth restriction and pulmonary hypertension in premature infants with bronchopulmonary dysplasia. J Perinatology, 33(7), 553–7. doi: 10.1038/jp.2012.164
Shinwell, E. S., Portnov, I., Meerpohl, J. J., Karen, T., & Bassler, D. (2016). Inhaled Corticosteroids for Bronchopulmonary Dysplasia: A Meta-analysis. Pediatrics, 138(6), pii: e20162511
Schneibel, K. R., Fitzpatrick, A. M., Ping, X-D., Brown, L.-A. S., & Gauthier, T. W. (2013). Inflammatory mediator patterns in tracheal aspirate and their association with bronchopulmonary dysplasia in very low birth weight neonates. J Perinatology, 33(5), 383–387. doi: 10.1038/jp.2012.125
Patra, K., Greene, M. M., & Silvestri, J. M. (2015) Neurodevelopmental impact of hydrocortisone exposure in extremely low birth weight infants: outcomes at 1 and 2 years. J Perinatology, 35(1), 77–81. doi: 10.1038/jp.2014.133
Stark, A. R., Carlo, W. A., Vohr, B. R., Papile, L. A., Saha, S., Bauer, C. R., et al. (2014). Death or neurodevelopmental impairment at 18 to 22 months in a randomized trial of early dexamethasone to prevent death or chronic lung disease in extremely low birth weight infants. J Pediatr., 164(1), 34–39. doi: 10.1016/j.jpeds.2013.07.027
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
